litlas
Log inCreate account

David Klatzmann

Active 1984–2025

Also published as
DAVID KLATZMANN
152
Papers
26,414
Citations
90
h-index
140
i10-index

Citations

Citations per year for David Klatzmann1984: 28 citations1985: 89 citations1986: 145 citations1987: 170 citations1988: 165 citations1989: 124 citations1990: 114 citations1991: 89 citations1992: 91 citations1993: 59 citations1994: 56 citations1995: 58 citations1996: 53 citations1997: 53 citations1998: 71 citations1999: 75 citations2000: 90 citations2001: 63 citations2002: 80 citations2003: 102 citations2004: 106 citations2005: 136 citations2006: 146 citations2007: 186 citations2008: 140 citations2009: 140 citations2010: 130 citations2011: 164 citations2012: 159 citations2013: 154 citations2014: 156 citations2015: 185 citations2016: 191 citations2017: 178 citations2018: 253 citations2019: 653 citations2020: 708 citations2021: 742 citations2022: 763 citations2023: 561 citations2024: 877 citations2025: 484 citations2026: 20 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,314 citing papers, 30.7% of this breakdownChina: 1,026 citing papers, 9.5% of this breakdownFrance: 848 citing papers, 7.9% of this breakdownUnited Kingdom: 711 citing papers, 6.6% of this breakdownGermany: 618 citing papers, 5.7% of this breakdownItaly: 461 citing papers, 4.3% of this breakdownJapan: 334 citing papers, 3.1% of this breakdownNetherlands: 315 citing papers, 2.9% of this breakdownCanada: 314 citing papers, 2.9% of this breakdownAustralia: 291 citing papers, 2.7% of this breakdownSweden: 206 citing papers, 1.9% of this breakdownSpain: 205 citing papers, 1.9% of this breakdown
0%30.7%Other 19.9%

Institutions

Fields

  • Immunology and Microbiology42%
  • Medicine37%
  • Biochemistry, Genetics and Molecular Biology15.2%
  • Neuroscience2.7%
  • Environmental Science0.5%
  • Agricultural and Biological Sciences0.5%
  • Other2.1%

Topics

  • Immune Cell Function and Interaction9.5%
  • T-cell and B-cell Immunology8.2%
  • Immunotherapy and Immune Responses4.8%
  • HIV Research and Treatment4.4%
  • Cancer Immunotherapy and Biomarkers2.7%
  • Atherosclerosis and Cardiovascular Diseases2.2%
  • Other68.2%

Coauthors

All papers

Open in search
  1. A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers

    Authors: Marine Fidelle, Conrad Rauber, Carolina Alves Costa Silva, Ai-Ling Tian, Imran Lahmar, Anne-Laure Mallard de La Varende, Liwei Zhao, Cassandra Thélémaque, Isabelle Lebhar, Meriem Messaoudene, Eugénie Pizzato, Roxanne Birebent, Maxime Descartes Mbogning Fonkou, Silvia Zoppi, Anna Reni, Cécile Dalban, Marion Leduc, Gladys Ferrere, Sylvère Durand, Pierre Ly, Aymeric Silvin, Kevin Mulder, Charles‐Antoine Dutertre, Florent Ginhoux, Satoru Yonekura, María Paula Roberti, Maryam Tidjani Alou, Safae Terrisse, Jianzhou Chen, Oliver Kepp, Angela Schippers, Norbert Wagner, Javier Suárez-Gosálvez, Sebastian Kobold, Jean‐Eudes Fahrner, Corentin Richard, Jacques Bosq, Leonardo Lordello, Giacomo Vitali, Nathalie Galleron, Benoît Quinquis, Emmanuelle Le Chatelier, Lucas Blanchard, Jean‐Philippe Girard, Anne Jarry, Nadine Gervois, Emmanuelle Godefroy, Nathalie Labarrière, Ronald Koschny, Romain Daillère, Benjamin Besse, Caroline Truntzer, François Ghiringhelli, Nicolas Coatnoan, Vanessa Mhanna, David Klatzmann, Damien Drubay, Laurence Albigès, Andrew Maltez Thomas, Nicola Segata, François‐Xavier Danlos, Aurélien Marabelle, Bertrand Routy, Lisa Derosa, Guido Kroemer, Laurence Zitvogel - Science 2023 cited by 221

  2. Cross-reactivity between tumor MHC class I–restricted antigens and an enterococcal bacteriophage

    Authors: Aurélie Fluckiger, Romain Daillère, Mohamed Sassi, Barbara S. Sixt, Peng Liu, Friedemann Loos, Corentin Richard, Catherine Rabu, Maryam Tidjani Alou, Anne‐Gaëlle Goubet, Fabien Lemaître, Gladys Ferrere, Lisa Derosa, Connie P.M. Duong, Meriem Messaoudene, Andréanne Gagné, Philippe Joubert, Luisa De Sordi, Laurent Debarbieux, Sylvain Simon, Clara‐Maria Scarlata, Maha Ayyoub, Belinda Palermo, Francesco Facciolo, Romain Boidot, Richard Wheeler, Ivo G. Boneca, Zsófia Sztupinszki, Krisztián Papp, István Csabai, Edoardo Pasolli, Nicola Segata, Carlos López-Otı́n, Zoltán Szállási, Fabrice André, Valerio Iebba, Valentin Quiniou, David Klatzmann, Jacques Bou Khalil, S. Khelaifia, Didier Raoult, Laurence Albigès, Bernard Escudier, Alexander Eggermont, Fathia Mami‐Chouaib, Paola Nisticò, François Ghiringhelli, Bertrand Routy, Nathalie Labarrière, Vincent Cattoir, Guido Kroemer, Laurence Zitvogel - Science 2020 cited by 384

  3. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis

    Authors: Joe‐Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Léonard-Louis, Stéphane Éderhy, Alban Redheuil, Samia Boussouar, Lee S. Nguyen, Adrien Procureur, Frederic Stein, Charlotte Fenioux, Perrine Devos, Paul Gougis, Martin Dres, Alexandre Demoule, Dimitri Psimaras, Timothée Lenglet, Thierry Maisonobe, Marc Pineton de Chambrun, Guillaume Hékimian, Christian Straus, Jésus Gonzalez‐Bermejo, David Klatzmann, Aude Rigolet, Perrine Guillaume-Jugnot, Nicolas Champtiaux, Olivier Benvéniste, Nicolas Weiss, Samir Saheb, Philippe Rouvier, Isabelle Plu, Estelle Gandjbakhch, Mathieu Kernéis, Nadjib Hammoudi, Noël Zahr, Claudia Llontop, Capucine Morélot‐Panzini, Lorenz Lehmann, Juan Qin, Javid J. Moslehi, Michèlle Rosenzwajg, Thomas Similowski, Yves Allenbach - Cancer Discovery 2023 cited by 202

  4. The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases

    Authors: David Klatzmann, Abul K. Abbas - Nature reviews. Immunology 2015 cited by 619

  5. Natural regulatory T cells control the development of atherosclerosis in mice

    Authors: Hafid Ait‐Oufella, Benoı̂t L. Salomon, Stéphane Potteaux, Anna-Karin L. Robertson, Pierre Gourdy, Joffrey Zoll, Régine Merval, Bruno Esposito, José L. Cohen, Sylvain Fisson, Richard A. Flavell, Göran K. Hansson, David Klatzmann, Alain Tedgui, Ziad Mallat - Nature Medicine 2006 cited by 1,086

  6. Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

    Authors: Michèlle Rosenzwajg, Roberta Lorenzon, P. Cacoub, Hang‐Phuong Pham, Fabien Pitoiset, Karim El Soufi, Claire Ribet, Claude C.A. Bernard, S. Aractingi, Beatrice Banneville, Laurent Beaugerie, Francis Bérenbaum, Julien Champey, Olivier Chazouillères, Christophe Corpechot, Bruno Fautrel, A. Mékinian, Elodie Régnier, David Saadoun, Joe‐Elie Salem, Jérémie Sellam, Philippe Seksik, Anne Daguenel-Nguyen, Valérie Doppler, Jéremie Mariau, Éric Vicaut, David Klatzmann - Annals of the Rheumatic Diseases 2018 cited by 402

  7. Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial

    Authors: Jens Y. Humrich, P. Cacoub, Michèlle Rosenzwajg, Fabien Pitoiset, Hang Phuong Pham, Joel Guidoux, David Leroux, Thomas Vazquez, Gabriela Riemekasten, Josef S Smolen, George C. Tsokos, David Klatzmann - Annals of the Rheumatic Diseases 2022 cited by 114

  8. Regulatory T cells in the treatment of disease

    Authors: Amir Sharabi, Maria Tsokos, Ying Ding, Thomas R. Malek, David Klatzmann, George C. Tsokos - Nature Reviews Drug Discovery 2018 cited by 295

  9. Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer’s disease mice

    Authors: Sandro Alves, Guillaume Churlaud, Mickaël Audrain, Kristin Michaelsen‐Preusse, Romain Fol, Benoît Souchet, Jérôme Braudeau, Martin Körte, David Klatzmann, Nathalie Cartier - Brain 2016 cited by 176

  10. Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

    Authors: Agnès Hartemann, G. Bensimon, Christine Payan, Sophie Jacqueminet, Olivier Bourron, Nathalie Nicolas, Michèle Fonfrède, Michèlle Rosenzwajg, Claude C.A. Bernard, David Klatzmann - The Lancet Diabetes & Endocrinology 2013 cited by 422

  11. Paracrine effect of regulatory T cells promotes cardiomyocyte proliferation during pregnancy and after myocardial infarction

    Authors: Serena Zacchigna, Valentina Martinelli, Silvia Moimas, Andrea Colliva, Marco Anzini, Andrea Nordio, Alessia Costa, Michael Rehman, Simone Vodret, Cristina Pierro, Giulia Colussi, Lorena Zentilin, María Inés Gutiérrez, Ellen Dirkx, Carlin S. Long, Gianfranco Sinagra, David Klatzmann, Mauro Giacca - Nature Communications 2018 cited by 202

  12. Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis

    Authors: David Saadoun, Michèlle Rosenzwajg, Florence Joly, Adrien Six, Fabrice Carrat, Vincent Thibault, D. Sène, P. Cacoub, David Klatzmann - New England Journal of Medicine 2011 cited by 746

  13. Regulatory T-Cell Response to Low-Dose Interleukin-2 in Ischemic Heart Disease

    Authors: Tian Zhao, Rouchelle Sriranjan, Zewen Kelvin Tuong, Yuning Lu, Andrew P. Sage, Meritxell Nus, Annette Hubsch, Fotini Kaloyirou, Evangelia Vamvaka, Joanna Helmy, Michalis Kostapanos, Navazh Jalaludeen, David Klatzmann, Alain Tedgui, James H.F. Rudd, Sarah J. Horton, Brian J.P. Huntly, Stephen P. Hoole, Simon P. Bond, Menna R. Clatworthy, Joseph Cheriyan, Ziad Mallat - NEJM Evidence 2021 cited by 62

  14. Use of machine learning in osteoarthritis research: a systematic literature review

    Authors: Marie Binvignat, Valentina Pedoia, Atul J. Butte, Karine Louati, David Klatzmann, Françis Berenbaum, Encarnita Mariotti‐Ferrandiz, Jérémie Sellam - RMD Open 2022 cited by 83

  15. Low-dose IL-2 in children with recently diagnosed type 1 diabetes: a Phase I/II randomised, double-blind, placebo-controlled, dose-finding study

    Authors: Michèlle Rosenzwajg, Randa Salet, Roberta Lorenzon, Nicolas Tchitchek, Alexandra Roux, Claude C.A. Bernard, Jean‐Claude Carel, Caroline Storey, Michel Polak, Jacques Beltrand, Chloé Amouyal, Agnès Hartemann, Pierre Corbeau, Éric Vicaut, Cecile Bibal, Pierre Bougnères, Tú-Anh Tran, David Klatzmann - Diabetologia 2020 cited by 105

  16. Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

    Authors: Michèlle Rosenzwajg, Guillaume Churlaud, Roberto Mallone, Adrien Six, Nicolas Dérian, Wahiba Chaara, Roberta Lorenzon, S. Alice Long, Jane H. Buckner, Georgia Afonso, Hang‐Phuong Pham, Agnès Hartemann, Aixin Yu, Alberto Pugliese, Thomas R. Malek, David Klatzmann - Journal of Autoimmunity 2015 cited by 249

  17. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities

    Authors: Yves Allenbach, C. Anquetil, Ali Manouchehri, Olivier Benvéniste, Olivier Lambotte, Bénédicte Lebrun‐Vignes, Jean‐Philippe Spano, Stéphane Éderhy, David Klatzmann, Michèlle Rosenzwajg, Bruno Fautrel, Jacquès Cadranel, Douglas B. Johnson, Javid J. Moslehi, Joe‐Elie Salem - Autoimmunity Reviews 2020 cited by 141

  18. Estrogen-mediated downregulation of AIRE influences sexual dimorphism in autoimmune diseases

    Authors: Nadine Dragin, Jacky Bismuth, Géraldine Cizeron-Clairac, Maria Grazia Biferi, Claire Berthault, Alain Serraf, Rémi Nottin, David Klatzmann, Ana Cumano, Martine Barkats, Rozen Le Panse, Sonia Berrih‐Aknin - Journal of Clinical Investigation 2016 cited by 199

  19. Selective IL-2 Responsiveness of Regulatory T Cells Through Multiple Intrinsic Mechanisms Supports the Use of Low-Dose IL-2 Therapy in Type 1 Diabetes

    Authors: Aixin Yu, Isaac Snowhite, Francesco Vendrame, Michèlle Rosenzwajg, David Klatzmann, Alberto Pugliese, Thomas R. Malek - Diabetes 2015 cited by 207

  20. TGF-β and VEGF cooperatively control the immunotolerant tumor environment and the efficacy of cancer immunotherapies

    Authors: Tristan Courau, Djamel Nehar-Belaid, Laura V. Flórez, Béatrice Levacher, Thomas Vazquez, Faustine Brimaud, Bertrand Bellier, David Klatzmann - JCI Insight 2016 cited by 127

  21. Effect of Intracoronary Administration of AAV1/SERCA2a on Ventricular Remodelling in Patients with Advanced Systolic Heart Failure: Results from the Agent-Hf Randomized Phase 2 Trial

    Authors: Jean‐Sébastien Hulot, Joe‐Elie Salem, Alban Redheuil, Jean‐Philippe Collet, S. Varnous, Patrick Jourdain, Damien Logeart, Estelle Gandjbakhch, Claude C.A. Bernard, Stéphane Hatem, Richard Isnard, Philippe Cluzel, Claude Le Feuvre, Pascal Leprince, Nadjib Hammoudi, François M. Lemoine, David Klatzmann, Éric Vicaut, Michel Komajda, Gilles Montalescot, Anne‐Marie Lompré, Roger J. Hajjar - European Journal of Heart Failure 2017 cited by 112

  22. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells

    Authors: Yenkel Grinberg‐Bleyer, Audrey Baeyens, Sylvaine You, Rima Elhage, Gwladys Fourcade, Sylvie Grégoire, Nicolas Cagnard, Wassila Carpentier, Qizhi Tang, Jeffrey A. Bluestone, Lucienne Chatenoud, David Klatzmann, Benoı̂t L. Salomon, Eliane Piaggio - The Journal of Experimental Medicine 2010 cited by 417

  23. T fr cells lack IL-2Rα but express decoy IL-1R2 and IL-1Ra and suppress the IL-1–dependent activation of T fh cells

    Authors: Paul-Gydéon Ritvo, Guillame Churlaud, Valentin Quiniou, Laura V. Flórez, Faustine Brimaud, Gwladys Fourcade, Encarnita Mariotti‐Ferrandiz, David Klatzmann - Science Immunology 2017 cited by 151

  24. Benchmarking of T cell receptor repertoire profiling methods reveals large systematic biases

    Authors: Pierre Barennes, Valentin Quiniou, Mikhail Shugay, Evgeniy S. Egorov, Alexey N. Davydov, Dmitriy M. Chudakov, Imran Uddin, Mazlina Ismail, Theres Oakes, Benny Chain, Anne Eugster, Karl Kashofer, Peter P. Rainer, Samuel Darko, Amy Ransier, Daniel C. Douek, David Klatzmann, Encarnita Mariotti‐Ferrandiz - Nature Biotechnology 2020 cited by 131